Abstract
Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.
Original language | English (US) |
---|---|
Article number | e12965 |
Journal | Transplant Infectious Disease |
Volume | 20 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2018 |
Keywords
- UL97 mutation
- cytomegalovirus
- ganciclovir resistance
- heart transplant
- letermovir
ASJC Scopus subject areas
- Transplantation
- Infectious Diseases